Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus
A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 567 participants.
Also called NCT05366868
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 567 participants
- Sponsor
- National Center for Global Health and Medicine, Japan
- Registry
-
NCT05366868 -
jRCTs051180211
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Japan
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05366868. Randomized; no masking; primary purpose treatment. Start 2022-05-26 (actual); primary completion 2026-08-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Imeglimin
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Vildagliptin
- Lead sponsor
- National Center for Global Health and Medicine, Japan
- Collaborator
- Sumitomo Pharma Co., Ltd.
Record details
- Record id
cardio:ct-nct05366868- Content hash
13be24372283d446ba8b0a2d6633bbc7ad02a75846e79259c0d05bba2acb56b6